Related Experiment Video

Updated: Sep 29, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

[Control of wound healing after glaucoma surgery. Effect and inhibition of the growth factor TGF-beta]

I Wimmer1, F Grehn

  • 1Universitäts-Augenklinik der Julius-Maximilians-Universität, Würzburg, Germany.

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|September 10, 2002
PubMed

Insights

Postoperative scarring after glaucoma surgery can be reduced by targeting TGF-beta 2. A novel antibody treatment shows promise as a safer alternative to current methods for preventing scarring.

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Fibrosis Biology

Context:

  • Trabeculectomy, a glaucoma surgery, often fails due to postoperative scarring of the filtering bleb.
  • Current anti-scarring treatments like 5-fluorouracil and mitomycin C have significant toxic side effects and cause patient stress.
  • Research is exploring growth factors, particularly TGF-beta 2, as key regulators of scarring in glaucoma.

Purpose:

  • To investigate the role of transforming growth factor-beta 2 (TGF-beta 2) in the induction of scarring after glaucoma surgery.
  • To evaluate the efficacy and safety of a human monoclonal anti-TGF-beta 2 antibody as a therapeutic alternative for preventing filtering bleb scarring.
  • To explore novel strategies for long-term scar inhibition in glaucoma patients.

Summary:

  • Elevated TGF-beta 2 levels in aqueous humor are observed in primary open-angle glaucoma.
  • In vitro and in vivo studies indicate that subconjunctival application of anti-TGF-beta 2 antibody effectively inhibits scarring.
  • This antibody treatment presents a potentially safe and well-tolerated approach to managing postoperative scarring.

Impact:

  • The anti-TGF-beta 2 antibody offers a promising, less toxic alternative to existing anti-scarring therapies in glaucoma surgery.
  • Further prospective studies are underway to confirm its role as a viable long-term solution for scar inhibition.
  • This research could lead to improved surgical outcomes and reduced patient morbidity in glaucoma management.

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...